| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","company":"SOLENO THERAPEUTICS INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_f4fdc847c7b0bf04","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","content_type":"text/plain","enriched_at":"2026-04-07T09:48:01.742663+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt","source_event_id":"evt_e91a2c4a3450","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"33ff80d2a81fbb6d","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.95,"dates_mentioned":["2026-04-05","2026-04-07"],"entities":[{"asset_class":"equity","name":"Soleno Therapeutics, Inc.","relevance":"issuer","symbol":"SLNO","type":"company"},{"asset_class":"equity","name":"Neurocrine Biosciences, Inc.","relevance":"acquirer","symbol":"NBIX","type":"company"}],"event_type":"merger_acquisition","information_gaps":["Details on the financial implications of the merger are not provided.","No information on the conditions for the tender offer's success beyond those mentioned."],"key_facts":["Merger agreement signed on April 5, 2026.","Tender offer price set at $53.00 per share.","Offer to purchase all outstanding shares of Soleno Therapeutics."],"numeric_claims":[{"label":"tender offer price","value":"$53.00"},{"label":"number of business days to commence offer","value":"10"},{"label":"number of business days offer will remain open","value":"20"}],"primary_claim":"Soleno Therapeutics entered into a merger agreement with Neurocrine Biosciences to commence a cash tender offer for its shares.","relevance_score":0.9,"sentiment":"positive","source_quality":"high","summary":"Soleno Therapeutics, Inc. filed an 8-K reporting a merger agreement with Neurocrine Biosciences, Inc., involving a cash tender offer for its shares at $53.00 each.","topics":["merger","acquisition","SEC filing"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 SOLENO THERAPEUTICS INC \u00b7 Filed 20260406","ticker":"SLNO","tickers":["SLNO"],"title":"SLNO filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-142911.txt"}... |